← All trials
NCT03221166
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2018
- Primary completion
- Oct 31, 2019
- Completion date
- Sep 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 124
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TriesteLead sponsor
- University of BresciaCollaborator
- University of TriesteStudy chair
- Centro di Riferimento Oncologico - AvianoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.